Are cYP1A2 genetic polymorphisms associated with treatment response to the antidepressant paroxetine?
Genetic variants in the CYP1A2 region may be indicators of treatment response in MDD patients to paroxetine.
We identified significant differences in disease characteristics and extraintestinal manifestations between AA and Ca IBD patients in a large tertiary care population. These results have implications for future genotype-phenotype studies.